Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Assets (2020 - 2025)

Bioventus (BVS) has disclosed Assets for 6 consecutive years, with $683.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets fell 6.1% year-over-year to $683.6 million, compared with a TTM value of $683.6 million through Dec 2025, down 6.1%, and an annual FY2025 reading of $683.6 million, down 6.1% over the prior year.
  • Assets was $683.6 million for Q4 2025 at Bioventus, down from $701.6 million in the prior quarter.
  • Across five years, Assets topped out at $1.4 billion in Q4 2022 and bottomed at $643.1 million in Q2 2021.
  • Average Assets over 5 years is $889.4 million, with a median of $769.5 million recorded in 2024.
  • The sharpest move saw Assets skyrocketed 147.92% in 2021, then crashed 40.92% in 2023.
  • Year by year, Assets stood at $1.2 billion in 2021, then rose by 11.97% to $1.4 billion in 2022, then plummeted by 40.92% to $810.9 million in 2023, then decreased by 10.23% to $728.0 million in 2024, then fell by 6.1% to $683.6 million in 2025.
  • Business Quant data shows Assets for BVS at $683.6 million in Q4 2025, $701.6 million in Q3 2025, and $706.8 million in Q2 2025.